Romania faces 680 million Pfizer bill after Belgian court ruling
Romania faces a €680 million bill from Pfizer—the largest single financial blow to its state budget in recent history—after a Belgian court ordered the payment over a disputed vaccine contract, Finance Minister Alexandru Nazare revealed in an exclusive interview with Digi24 on Wednesday. The sum, equivalent to roughly 0.3% of Romania’s annual GDP, must be settled within two months of receiving the court’s written justification, which has yet to arrive. Nazare confirmed that negotiations with Pfizer’s designated negotiator are ongoing, with Bucharest pushing for an installment plan to soften the fiscal shock.
The dispute stems from a 2021 agreement under which Romania purchased 10 million doses of the Pfizer-BioNTech vaccine. Legal battles erupted after Bucharest alleged that the contract contained irregularities, including inflated prices and opaque procurement procedures. The Belgian court’s ruling, delivered in absentia, now forces Romania to honor its obligations or face further penalties. “This is the most severe damage to our state budget in decades,” Nazare told Digi24. “We are exploring every legal and financial avenue to minimize the impact, but the clock is ticking.”
Analysts warn that the payment could force Romania to reallocate funds from critical social programs or delay infrastructure projects. The health ministry has already signaled that €200 million earmarked for hospital upgrades may need to be redirected. Opposition lawmakers have accused the government of mismanagement, demanding an emergency parliamentary session to scrutinize the original contract. “Taxpayers will foot the bill for bureaucratic failures,” said opposition leader Călin Popescu-Tăriceanu.
Pfizer, meanwhile, has remained tight-lipped about the ruling, with a company spokesperson stating only that it “respects the court’s decision and remains committed to dialogue.” The pharmaceutical giant’s legal team is reportedly preparing to enforce the judgment if Romania fails to comply within the 60-day window.
The case underscores broader tensions across Europe over pandemic-era contracts, with several countries still locked in disputes over vaccine procurement. In Hungary, a leaked government proposal suggests that billions in forint—funneled through opaque private equity funds—may have been misused in similar deals, though authorities deny wrongdoing . Meanwhile, the European Commission has urged member states to harmonize their legal strategies to avoid protracted litigation.
For Romania, the immediate priority is securing an installment agreement with Pfizer. Nazare hinted that Brussels could play a role in mediating the dispute, given the EU’s shared interest in avoiding further budgetary strain. “We are in constant contact with the European Commission,” he said. “This is not just Romania’s problem—it’s a European one.”










